Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc. develops genomic cures for patients suffering from severe diseases using proprietary zinc finger technology.

msh id	COM:SANGAMO
symbol	SGMO
name	Sangamo Therapeutics, Inc.
homepage url	https://www.sangamo.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	405
crunchbase url	-
linkedin url	-
founders	-

market cap	82.75M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.07
growth cost of revenue	0.83
growth depreciation and amortization	0.08
growth ebitda	0.54
growth ebitda ratio	0.71
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.02
growth gross profit	0.55
growth gross profit ratio	-0.02

COM:SANGAMO

Sangamo Therapeutics, Inc.

Last Close

1.95

21/11 21:00

Market Cap

82.75M

Beta: -

Volume Today

3.28M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	290.52M
cost of revenue	290.52M
depreciation and amortization	22.19M
ebitda	-92.1M
ebitda ratio	-0.52
eps	-1.48
eps diluted	-1.48
operating expenses	268.33M
operating income	-114.29M
operating income ratio	-0.65

accounts receivables	3.15M
capital expenditure	-21.16M
cash at beginning of period	100.44M
cash at end of period	45.2M
inventory	-
working capital ttm	99.09M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-